Expression of MAGE-1 and -3 genes and gene products in human hepatocellular carcinoma

Kariyama, Kazuya; Higashi, Toshihiro; Kobayashi, Yohnosuke; Nouso, Kazuhiro; Nakatsukasa, Harushige; Yamano, Toshihisa; Ishizaki, Masahiko; Kaneyoshi, Toshihiko; Toshikuni, Nobuyuki; Ohnishi, Teppei; Fujiwara, Keishi; Nakayama, Eiichi; Terracciano, Luigi; Spagnoli, Giulio C.; Tsuji, Takao

doi:10.1038/sj.bjc.6690810

Cited by 36 publications

(28 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite improvement in sonographic examinations and therapy for HCC, the outcome generally remains unsatisfactory. Recently, the expression of CT antigen-encoding genes in HCC tissues has been reported by several laboratories (7)(8)(9)(10). Our own data have revealed that mRNA for at least 20 CT antigens can be detected in HCC tissues.…”

Section: Introductionmentioning

confidence: 66%

The Spontaneous CD8+ T-Cell Response to HLA-A2-Restricted NY-ESO-1b Peptide in Hepatocellular Carcinoma Patients

Shang

Chen²,

Zhang

et al. 2004

Clinical Cancer Research

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 66%

The Spontaneous CD8+ T-Cell Response to HLA-A2-Restricted NY-ESO-1b Peptide in Hepatocellular Carcinoma Patients

Shang

Chen²,

Zhang

et al. 2004

Clinical Cancer Research

View full text Add to dashboard Cite

“…One male patient of 36 malignant melanoma patients with stage IV lung metastasis had antibody against TSGA10. CT antigens generally induce a low frequency of antibody responses in cancer patients irrespective of the high frequency of expression of some CT antigens such as MAGE-1 (80%) in HCC (13), SSX (75%) in synovial sarcoma (34) with the exception of NY-ESO-1 (31). Wang et al (40) isolated 55 different antigens by SEREX-screening 4 HCC cDNA libraries with autologous or allogeneic sera.…”

Section: Discussionmentioning

confidence: 99%

Over‐Expression of the Testis‐Specific Gene TSGA10 in Cancers and Its Immunogenicity

Tanaka

Ono

Sato

et al. 2004

Microbiology and Immunology

View full text Add to dashboard Cite

Human tumor antigens recognized by an autologous host have been identified, and the list of antigens recognized by CD8 T cells (9,25,36,37), CD4 T cells (3,10,24,39), and antibodies (8,21,26) is rapidly growing. They can be categorized into the following groups: differentiation antigens (2,5,14), mutational antigens (27), amplified/over-expressed antigens (23), splice variant antigens (26, 28), viral antigens (16, 33), and cancer/testis (CT) antigens (4, 26). CT antigens have received particular attention because of their unique expression pattern and potential as targets for cancer vaccines (29,41). The characteristics of CT antigens include high levels of expression in male germ cells, lack of expression in other normal tissues, and aberrant expression in a wide range of tumors. There are now more than 20 genes or gene families known to code for CT antigens (29, 41).The identification of CT antigens has been primarily based on the detection of the candidate antigen/gene in tumors followed by their characterization using a panel of normal tissues and various tumors. The testis-specific expression of CT antigens may prompt one to investigate whether previously defined sperm proteins are also expressed in tumors. We have been studying the expression in tumors of proacrosin binding protein sp32 precursor present in spermatozoa (22) and A-kinase anchoring protein 3 (AKAP3) present in the sperm head and flagellum (7). Real-time RT-PCR analysis using a TaqMan probe showed mRNA over-expression associated with those sperm proteins in some tumors compared to corresponding normal tissues. In this study, we investigated TSGA10 mRNA expression in normal tissues and tumors. TSGA10 was originally identified by differential mRNA display as a testis-specific gene (18,19). Quantitative real-time RT-PCR analysis showed over-expres- Editor-Communicated Paper Over-Expression of the Testis-Specific Gene

show abstract

“…12,13 MAGE expression has been found in a wide array of neoplastic lesions and is most prevalent in malignant melanomas, several types of carcinomas, and certain sarcomas. [14][15][16][17][18][19][20] NY-ESO-1 21,22 has been isolated in esophageal carcinoma but has also been found in several other malignancies, such as melanoma; neuroblastoma; carcinoma of the ovary, breast, and lung; and in synovial sarcoma. [23][24][25][26][27][28][29] The CT7 antigen was identified by the SEREX approach using a melanoma cell line SK-MEL37 and allogeneic sera from a melanoma patient.…”

mentioning

confidence: 99%

Expression of cancer–testis antigens in endometrial carcinomas using a tissue microarray

et al. 2005

View full text Add to dashboard Cite

Cancer-testis (CT) antigens are expressed in a variety of malignant tumors, but in normal adult tissue, they are only expressed in testicular germ cells. Owing to this tumor-associated expression pattern, these antigens are of major interest as potential targets for immunotherapy and possibly for diagnostic purposes. This study was performed to analyze the expression of four CT antigens, NY-ESO-1, MAGE-A3, MAGE-A4, and CT7/MAGE-C1, in endometrial carcinoma using immunohistochemistry, and to correlate expression with histologic subtypes, grade, and expression of WT1 and p53. Formalin-fixed paraffin-embedded tissues of 130 endometrial carcinomas of the following types and grades were analyzed using a tissue microarray: 85 endometrioid carcinomas (FIGO grade 1, 39; grade 2, 11; and grade 3, 35), 18 papillary serous carcinomas, 12 clear cell carcinomas, 13 malignant mixed mullerian tumors, one mucinous adenocarcinoma, and one undifferentiated carcinoma. The following anti-CT monoclonal antibodies/antigens were studied by immunohistochemistry: monoclonal antibody ES121/NY-ESO-1, monoclonal antibody M3H67/MAGE-A3, monoclonal antibody 57B/ MAGE-A4, and monoclonal antibody CT7-33/CT7. The CT expression data were compared to WT1 and p53 protein expression as analyzed in a previous study. Positive staining with anti-CT monoclonal antibodies was graded as follows: focal, o5% positive cells; 1 þ , 5-25% cells; 2 þ , 26-50% cells; 3 þ , 51-75%; and 4 þ , 475% cells. The 3 þ and 4 þ staining patterns were considered homogeneous patterns of potential clinical significance and were scored positive for statistical analysis. In low-grade tumors, the most immunoreactivity was seen with mAb M3H67 but little labeling was observed with the other monoclonal antibodies. In high-grade tumors, monoclonal antibodies M3H67 (25%), 57B (23%), and CT7-33 (20%) showed the highest reactivity, while ES121 showed the lowest immunoreactivity (6%). The staining pattern was mostly heterogeneous. Statistical significance was found solely for the correlation of monoclonal antibody 57B staining and p53 expression. No correlation was found for any anti-CT monoclonal antibody staining and clinical stage or for anti-CT staining and WT1 expression. CT antigens CT7, MAGE-A3 and MAGE-A4, but not NY-ESO-1, are expressed in high-grade endometrial carcinomas, and expression of MAGE-A4 is correlated with the presence of overexpressed p53.

show abstract

Expression of MAGE-1 and -3 genes and gene products in human hepatocellular carcinoma

Cited by 36 publications

References 29 publications

The Spontaneous CD8+ T-Cell Response to HLA-A2-Restricted NY-ESO-1b Peptide in Hepatocellular Carcinoma Patients

The Spontaneous CD8+ T-Cell Response to HLA-A2-Restricted NY-ESO-1b Peptide in Hepatocellular Carcinoma Patients

Over‐Expression of the Testis‐Specific Gene TSGA10 in Cancers and Its Immunogenicity

Expression of cancer–testis antigens in endometrial carcinomas using a tissue microarray

Contact Info

Product

Resources

About